Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Combination With Chemotherapy in AML
NCT04547062Phase 1Completed
- Sponsor
- CHU de Nantes
- Start
- Dec 2020
- Primary completion
- Apr 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1 trial of tocilizumab in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Primary endpoint: Dose-Limiting Toxicity at 45 days. Started Dec 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04547062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547062.